Clinical Trial

A Study of Remternetug (LY3372993) in Healthy Chinese Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 25 weeks, including screening period.
Protocol Amendment History 2 changes
minor Completion moved earlier: 2027-01 -> 2026-08 2026-06-18
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-21
Trial Details
NCT Number NCT07346495
Lead Sponsor Eli Lilly and Company
Conditions Healthy
Enrollment 24 participants
Start Date 2026-01-31
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-17